Evommune filed for an initial public offering to support development of two mid‑stage assets: EVO756, an oral MRGPRX2 antagonist aimed at mast‑cell driven diseases, and EVO301, an IL‑18 neutralizer in phase 2. The company plans to use proceeds to complete ongoing trials and expand clinical programs for chronic spontaneous urticaria and atopic dermatitis. Evommune reported encouraging early data for EVO756 and expects multiple phase‑2 readouts next year; the filing disclosed cash runway and outlined plans to expand indications if efficacy signals hold. The IPO signals renewed appetite for inflammation assets and may draw investor interest in differentiated oral and biologic approaches for mast‑cell and cytokine‑mediated diseases. Context: MRGPRX2 is a GPCR linked to non‑IgE mast‑cell activation and pruritic inflammation, making an oral antagonist an attractive alternative to injectable biologics for some patients.